Summary: Matador raised approximately $1.2 million in gross proceeds through its ATM Program during its first quarterly reporting period, with capital deployment via the ATM Program supporting Bitcoin ...

The Company acquired 2.0 Bitcoin at an average price of approximately US$74,906 per Bitcoin, inclusive of fees and expenses. The acquisition was funded using proceeds raised under the ATM Program, ...

The Company acquired 2.0 Bitcoin at an average price of approximately US$74,906 per Bitcoin, inclusive of fees and expenses. The acquisition was funded using proceeds raised under the ATM Program, ...

On March 23, 2026, Strategy Inc. (formerly MicroStrategy) filed a comprehensive Form 8-K with the Securities and Exchange Commission, signaling a dramatic expansion of its ability to raise capital to ...

TORONTO--(BUSINESS WIRE)--Granite Real Estate Investment Trust (TSX: GRT.UN) (“Granite” or the “Trust”) announced today the renewal of its $250 million at-the-market equity distribution program (the ...

ATLANTA--(BUSINESS WIRE)-- NCR Atleos (NATL) Corporation (NYSE: NATL) (“Atleos”), a leader in expanding self-service financial access for financial institutions, retailers and consumers, today ...

NCR Atleos Corporation (NYSE: NATL) (“Atleos”), a leader in expanding self-service financial access for financial institutions, retailers and consumers, today announced an advancement in the ...

The company revealed Tuesday morning that it has established the capacity to sell up to $300 million in common stock at its sole discretion. This program is pursuant to a shelf registration statement ...

NCR Atleos Corporation, a leader in expanding self-service financial access for financial institutions, retailers and consumers, today announced an advancement in the dual-sided ATM concept, ...

Fuelcell Energy ( (FCEL)) has shared an announcement. On December 30, 2025, FuelCell Energy amended its Open Market Sale Agreement with a syndicate of sales agents including Jefferies, B. Riley ...

SAB Biotherapeutics ( (SABS)) has provided an update. On December 29, 2025, SAB Biotherapeutics, Inc. entered into a new sales agreement with UBS Securities LLC to establish an at-the-market equity ...